Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

AstraZeneca
Farmers Insurance
Cipla
Novartis
Deloitte
Merck
UBS
Fuji
Cantor Fitzgerald
Teva

Generated: August 20, 2017

DrugPatentWatch Database Preview

RYTHMOL Drug Profile

« Back to Dashboard

Which patents cover Rythmol, and when can generic versions of Rythmol launch?

Rythmol is a drug marketed by Glaxosmithkline Llc and is included in two NDAs.

The generic ingredient in RYTHMOL is propafenone hydrochloride. There are eleven drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the propafenone hydrochloride profile page.

Summary for Tradename: RYTHMOL

Patents:0
Applicants:1
NDAs:2
Bulk Api Vendors: see list42
Clinical Trials: see list2
Patent Applications: see list461
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:RYTHMOL at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline Llc
RYTHMOL
propafenone hydrochloride
TABLET;ORAL019151-001Nov 27, 1989ABRXYesNo► Subscribe► Subscribe► Subscribe
Glaxosmithkline Llc
RYTHMOL SR
propafenone hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL021416-001Sep 4, 2003ABRXYesNo► Subscribe► Subscribe► Subscribe
Glaxosmithkline Llc
RYTHMOL
propafenone hydrochloride
TABLET;ORAL019151-003Nov 20, 1992ABRXYesNo► Subscribe► Subscribe► Subscribe
Glaxosmithkline Llc
RYTHMOL
propafenone hydrochloride
TABLET;ORAL019151-002Nov 27, 1989ABRXYesYes► Subscribe► Subscribe► Subscribe
Glaxosmithkline Llc
RYTHMOL SR
propafenone hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL021416-003Sep 4, 2003ABRXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: RYTHMOL

Drugname Dosage Strength RLD Submissiondate
propafenoneExtended-release Capsules325 mgRythmol SR11/7/2006
propafenone hydrochlorideExtended-release Capsules225 mg and 425 mgRythmol SR10/11/2006
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Johnson and Johnson
US Department of Justice
Julphar
Moodys
Dow
Mallinckrodt
Fish and Richardson
Argus Health
Queensland Health
Novartis

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot